Your browser doesn't support javascript.
loading
Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?
Prince, David Stephen; Girolamo, Julia Di; Pipicella, Joseph Louis; Bagatella, Melissa; Kayes, Tahrima; Alvaro, Frank; Maley, Michael; Foo, Hong; Middleton, Paul MacConachie; Levy, Miriam Tania.
Afiliação
  • Prince DS; Liverpool Hospital, Sydney, NSW, Australia.
  • Girolamo JD; The Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
  • Pipicella JL; The University of NSW, Sydney, NSW, Australia.
  • Bagatella M; Liverpool Hospital, Sydney, NSW, Australia.
  • Kayes T; The Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
  • Alvaro F; Liverpool Hospital, Sydney, NSW, Australia.
  • Maley M; The Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
  • Foo H; Liverpool Hospital, Sydney, NSW, Australia.
  • Middleton PM; Liverpool Hospital, Sydney, NSW, Australia.
  • Levy MT; The Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
Can J Gastroenterol Hepatol ; 2022: 3449938, 2022.
Article em En | MEDLINE | ID: mdl-36276913
ABSTRACT
Case detection remains a major challenge for hepatitis C virus (HCV) elimination. We have previously published results from a pilot of an emergency department (ED) semiautomated screening program, SEARCH; Screening Emergency Admissions at Risk of Chronic HCV. Several refinements to SEARCH have been developed to streamline and reduce cost. All direct costs of HCV testing until direct-acting antiviral (DAA) therapy initiation were calculated. Cost was assessed in 2018 Australian Dollars. A cost analysis of the initial program and refinements are presented. Sensitivity analysis to understand impact of variation in staff time, laboratory test cost, changes in HCV antibody (Ab) prevalence, RNA positivity percentage, and rate of linkage to care was conducted. Impact of refinements (SEARCH (2)) to cost is presented. The total SEARCH pilot, testing 5000 patients was estimated to cost $110,549.52 (range $92,109.79-$129,581.24) comprising of $68,278.67 for HCV Ab testing, $21,568.99 for follow-up and linkage to care of positive patients and $20,701.86 to prepare HCV RNA positive patients for treatment. Internal program refinements resulted in a 25% cost reduction. Following refinements, the cost of HCV antibody screening was $8.46 per test and the total cost per positive HCV Ab, positive HCV RNA, and per treated patient were $611.77, $2,168.64, and $3,566.11, respectively. Our sensitivity analysis indicates costs per HCV case found are modest so long as HCV Ab prevalence was at least 1%. ED screening is an affordable strategy for HCV case detection and elimination.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Can J Gastroenterol Hepatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatite C Crônica Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Can J Gastroenterol Hepatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália